nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Hypersplenism—Hydroxyurea—head and neck cancer	0.155	0.212	CcSEcCtD
Epoprostenol—Catheter related infection—Fluorouracil—head and neck cancer	0.0395	0.054	CcSEcCtD
Epoprostenol—Device related infection—Fluorouracil—head and neck cancer	0.0308	0.0422	CcSEcCtD
Epoprostenol—PTGIS—Nicotinamide salvaging—PTGS2—head and neck cancer	0.0258	0.0959	CbGpPWpGaD
Epoprostenol—Pain in jaw—Vinblastine—head and neck cancer	0.025	0.0342	CcSEcCtD
Epoprostenol—PTGIS—Nicotinate metabolism—PTGS2—head and neck cancer	0.0137	0.0511	CbGpPWpGaD
Epoprostenol—Platelet count decreased—Hydroxyurea—head and neck cancer	0.0125	0.0171	CcSEcCtD
Epoprostenol—Application site pain—Fluorouracil—head and neck cancer	0.0122	0.0166	CcSEcCtD
Epoprostenol—PTGIS—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—head and neck cancer	0.0113	0.0421	CbGpPWpGaD
Epoprostenol—Skin ulcer—Hydroxyurea—head and neck cancer	0.00954	0.0131	CcSEcCtD
Epoprostenol—Rectal haemorrhage—Vinblastine—head and neck cancer	0.00902	0.0123	CcSEcCtD
Epoprostenol—Cellulitis—Vinblastine—head and neck cancer	0.00896	0.0123	CcSEcCtD
Epoprostenol—Ascites—Docetaxel—head and neck cancer	0.00849	0.0116	CcSEcCtD
Epoprostenol—Chest tightness—Docetaxel—head and neck cancer	0.00823	0.0113	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—CEBPA—head and neck cancer	0.00803	0.0299	CbGpPWpGaD
Epoprostenol—PTGIS—Eicosanoid Synthesis—PTGS2—head and neck cancer	0.00735	0.0273	CbGpPWpGaD
Epoprostenol—PTGIS—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00694	0.0258	CbGpPWpGaD
Epoprostenol—PTGIS—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00687	0.0256	CbGpPWpGaD
Epoprostenol—Pulmonary oedema—Hydroxyurea—head and neck cancer	0.00661	0.00904	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—STAT6—head and neck cancer	0.00642	0.0239	CbGpPWpGaD
Epoprostenol—PTGIS—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.00615	0.0229	CbGpPWpGaD
Epoprostenol—Hepatic failure—Hydroxyurea—head and neck cancer	0.006	0.00821	CcSEcCtD
Epoprostenol—PTGIS—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00594	0.0221	CbGpPWpGaD
Epoprostenol—Cellulitis—Fluorouracil—head and neck cancer	0.00588	0.00804	CcSEcCtD
Epoprostenol—PTGIS—Biological oxidations—NAT2—head and neck cancer	0.00546	0.0203	CbGpPWpGaD
Epoprostenol—Pleural effusion—Docetaxel—head and neck cancer	0.00504	0.00689	CcSEcCtD
Epoprostenol—Pancytopenia—Vinblastine—head and neck cancer	0.00485	0.00664	CcSEcCtD
Epoprostenol—PTGIS—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00481	0.0179	CbGpPWpGaD
Epoprostenol—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00481	0.0179	CbGpPWpGaD
Epoprostenol—Sepsis—Fluorouracil—head and neck cancer	0.00464	0.00635	CcSEcCtD
Epoprostenol—Depression—Vinblastine—head and neck cancer	0.00454	0.00621	CcSEcCtD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.0045	0.0167	CbGpPWpGaD
Epoprostenol—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.0045	0.0167	CbGpPWpGaD
Epoprostenol—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00449	0.00614	CcSEcCtD
Epoprostenol—Myocardial infarction—Vinblastine—head and neck cancer	0.00447	0.00611	CcSEcCtD
Epoprostenol—Pancytopenia—Hydroxyurea—head and neck cancer	0.00443	0.00605	CcSEcCtD
Epoprostenol—PTGER1—G alpha (q) signalling events—KISS1—head and neck cancer	0.0044	0.0164	CbGpPWpGaD
Epoprostenol—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00438	0.0163	CbGpPWpGaD
Epoprostenol—Chest discomfort—Docetaxel—head and neck cancer	0.00436	0.00597	CcSEcCtD
Epoprostenol—Infestation—Hydroxyurea—head and neck cancer	0.00416	0.00568	CcSEcCtD
Epoprostenol—Infestation NOS—Hydroxyurea—head and neck cancer	0.00416	0.00568	CcSEcCtD
Epoprostenol—Haemoglobin—Vinblastine—head and neck cancer	0.00411	0.00562	CcSEcCtD
Epoprostenol—Haemorrhage—Vinblastine—head and neck cancer	0.00409	0.00559	CcSEcCtD
Epoprostenol—PTGIS—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.00409	0.0152	CbGpPWpGaD
Epoprostenol—Hypoaesthesia—Vinblastine—head and neck cancer	0.00407	0.00557	CcSEcCtD
Epoprostenol—Pharyngitis—Vinblastine—head and neck cancer	0.00406	0.00555	CcSEcCtD
Epoprostenol—Cardiac failure—Fluorouracil—head and neck cancer	0.00398	0.00544	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00393	0.0146	CbGpPWpGaD
Epoprostenol—Pulmonary embolism—Docetaxel—head and neck cancer	0.00386	0.00528	CcSEcCtD
Epoprostenol—Injection site reaction—Docetaxel—head and neck cancer	0.00384	0.00525	CcSEcCtD
Epoprostenol—Haemoglobin—Hydroxyurea—head and neck cancer	0.00375	0.00513	CcSEcCtD
Epoprostenol—Influenza like illness—Docetaxel—head and neck cancer	0.00375	0.00513	CcSEcCtD
Epoprostenol—Haemorrhage—Hydroxyurea—head and neck cancer	0.00373	0.0051	CcSEcCtD
Epoprostenol—PTGER1—G alpha (q) signalling events—GRP—head and neck cancer	0.00362	0.0135	CbGpPWpGaD
Epoprostenol—Pulmonary oedema—Docetaxel—head and neck cancer	0.00344	0.0047	CcSEcCtD
Epoprostenol—Angiopathy—Hydroxyurea—head and neck cancer	0.00339	0.00463	CcSEcCtD
Epoprostenol—Sepsis—Docetaxel—head and neck cancer	0.00335	0.00458	CcSEcCtD
Epoprostenol—Chills—Hydroxyurea—head and neck cancer	0.00335	0.00458	CcSEcCtD
Epoprostenol—Anaemia—Vinblastine—head and neck cancer	0.00329	0.0045	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00324	0.0121	CbGpPWpGaD
Epoprostenol—Pancytopenia—Fluorouracil—head and neck cancer	0.00319	0.00436	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00316	0.0118	CbGpPWpGaD
Epoprostenol—Hepatic failure—Docetaxel—head and neck cancer	0.00312	0.00426	CcSEcCtD
Epoprostenol—Pneumonia—Fluorouracil—head and neck cancer	0.00301	0.00411	CcSEcCtD
Epoprostenol—Anaemia—Hydroxyurea—head and neck cancer	0.003	0.00411	CcSEcCtD
Epoprostenol—Infestation NOS—Fluorouracil—head and neck cancer	0.00299	0.00409	CcSEcCtD
Epoprostenol—Infestation—Fluorouracil—head and neck cancer	0.00299	0.00409	CcSEcCtD
Epoprostenol—PTGIR—Endothelin Pathways—MAPK1—head and neck cancer	0.00296	0.011	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00295	0.011	CbGpPWpGaD
Epoprostenol—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00295	0.00403	CcSEcCtD
Epoprostenol—Myocardial infarction—Fluorouracil—head and neck cancer	0.00293	0.00401	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00291	0.0108	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00291	0.0108	CbGpPWpGaD
Epoprostenol—Urinary tract infection—Fluorouracil—head and neck cancer	0.00291	0.00398	CcSEcCtD
Epoprostenol—Cardiac failure—Docetaxel—head and neck cancer	0.00287	0.00393	CcSEcCtD
Epoprostenol—Thrombocytopenia—Vinblastine—head and neck cancer	0.00285	0.00389	CcSEcCtD
Epoprostenol—Epistaxis—Fluorouracil—head and neck cancer	0.00282	0.00386	CcSEcCtD
Epoprostenol—Sinusitis—Fluorouracil—head and neck cancer	0.00281	0.00384	CcSEcCtD
Epoprostenol—Anorexia—Vinblastine—head and neck cancer	0.00277	0.00379	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00275	0.00376	CcSEcCtD
Epoprostenol—Haemoglobin—Fluorouracil—head and neck cancer	0.0027	0.00369	CcSEcCtD
Epoprostenol—PTGIS—Biological oxidations—GSTM1—head and neck cancer	0.0027	0.01	CbGpPWpGaD
Epoprostenol—Rhinitis—Fluorouracil—head and neck cancer	0.00269	0.00368	CcSEcCtD
Epoprostenol—Haemorrhage—Fluorouracil—head and neck cancer	0.00269	0.00367	CcSEcCtD
Epoprostenol—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00267	0.00365	CcSEcCtD
Epoprostenol—Pharyngitis—Fluorouracil—head and neck cancer	0.00267	0.00364	CcSEcCtD
Epoprostenol—Oedema—Hydroxyurea—head and neck cancer	0.00265	0.00362	CcSEcCtD
Epoprostenol—Infection—Hydroxyurea—head and neck cancer	0.00263	0.0036	CcSEcCtD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—head and neck cancer	0.00262	0.00976	CbGpPWpGaD
Epoprostenol—Paraesthesia—Vinblastine—head and neck cancer	0.00261	0.00357	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00261	0.0097	CbGpPWpGaD
Epoprostenol—Nervous system disorder—Hydroxyurea—head and neck cancer	0.0026	0.00355	CcSEcCtD
Epoprostenol—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.0026	0.00355	CcSEcCtD
Epoprostenol—Skin disorder—Hydroxyurea—head and neck cancer	0.00257	0.00352	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00256	0.0035	CcSEcCtD
Epoprostenol—PTGIS—Biological oxidations—CYP1A1—head and neck cancer	0.00256	0.00952	CbGpPWpGaD
Epoprostenol—Anorexia—Hydroxyurea—head and neck cancer	0.00253	0.00346	CcSEcCtD
Epoprostenol—Decreased appetite—Vinblastine—head and neck cancer	0.00253	0.00346	CcSEcCtD
Epoprostenol—Pain—Vinblastine—head and neck cancer	0.00249	0.0034	CcSEcCtD
Epoprostenol—Constipation—Vinblastine—head and neck cancer	0.00249	0.0034	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—KISS1—head and neck cancer	0.00241	0.00897	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.0024	0.00892	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.0024	0.00892	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00238	0.00325	CcSEcCtD
Epoprostenol—Dyspnoea—Hydroxyurea—head and neck cancer	0.00236	0.00323	CcSEcCtD
Epoprostenol—Somnolence—Hydroxyurea—head and neck cancer	0.00236	0.00322	CcSEcCtD
Epoprostenol—Dyspepsia—Hydroxyurea—head and neck cancer	0.00233	0.00319	CcSEcCtD
Epoprostenol—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.00231	0.0086	CbGpPWpGaD
Epoprostenol—Decreased appetite—Hydroxyurea—head and neck cancer	0.0023	0.00315	CcSEcCtD
Epoprostenol—Pancytopenia—Docetaxel—head and neck cancer	0.0023	0.00314	CcSEcCtD
Epoprostenol—Abdominal pain—Vinblastine—head and neck cancer	0.0023	0.00314	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00229	0.00313	CcSEcCtD
Epoprostenol—Fatigue—Hydroxyurea—head and neck cancer	0.00229	0.00313	CcSEcCtD
Epoprostenol—Pain—Hydroxyurea—head and neck cancer	0.00227	0.0031	CcSEcCtD
Epoprostenol—Constipation—Hydroxyurea—head and neck cancer	0.00227	0.0031	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—UROD—head and neck cancer	0.00225	0.00837	CbGpPWpGaD
Epoprostenol—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00222	0.00827	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—KISS1—head and neck cancer	0.00222	0.00825	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—KISS1—head and neck cancer	0.00222	0.00825	CbGpPWpGaD
Epoprostenol—Weight decreased—Docetaxel—head and neck cancer	0.00219	0.003	CcSEcCtD
Epoprostenol—Pneumonia—Docetaxel—head and neck cancer	0.00217	0.00297	CcSEcCtD
Epoprostenol—Anaemia—Fluorouracil—head and neck cancer	0.00216	0.00295	CcSEcCtD
Epoprostenol—Infestation—Docetaxel—head and neck cancer	0.00216	0.00295	CcSEcCtD
Epoprostenol—Infestation NOS—Docetaxel—head and neck cancer	0.00216	0.00295	CcSEcCtD
Epoprostenol—Hypersensitivity—Vinblastine—head and neck cancer	0.00214	0.00293	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00213	0.00291	CcSEcCtD
Epoprostenol—Myocardial infarction—Docetaxel—head and neck cancer	0.00212	0.00289	CcSEcCtD
Epoprostenol—Body temperature increased—Hydroxyurea—head and neck cancer	0.0021	0.00287	CcSEcCtD
Epoprostenol—Asthenia—Vinblastine—head and neck cancer	0.00209	0.00285	CcSEcCtD
Epoprostenol—Epistaxis—Docetaxel—head and neck cancer	0.00204	0.00279	CcSEcCtD
Epoprostenol—Myalgia—Fluorouracil—head and neck cancer	0.00199	0.00272	CcSEcCtD
Epoprostenol—Chest pain—Fluorouracil—head and neck cancer	0.00199	0.00272	CcSEcCtD
Epoprostenol—Diarrhoea—Vinblastine—head and neck cancer	0.00199	0.00272	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—GRP—head and neck cancer	0.00198	0.00738	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00195	0.00267	CcSEcCtD
Epoprostenol—Haemoglobin—Docetaxel—head and neck cancer	0.00195	0.00266	CcSEcCtD
Epoprostenol—Rhinitis—Docetaxel—head and neck cancer	0.00194	0.00266	CcSEcCtD
Epoprostenol—Haemorrhage—Docetaxel—head and neck cancer	0.00194	0.00265	CcSEcCtD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—EGFR—head and neck cancer	0.00194	0.0072	CbGpPWpGaD
Epoprostenol—Hypoaesthesia—Docetaxel—head and neck cancer	0.00193	0.00264	CcSEcCtD
Epoprostenol—Confusional state—Fluorouracil—head and neck cancer	0.00192	0.00263	CcSEcCtD
Epoprostenol—Pharyngitis—Docetaxel—head and neck cancer	0.00192	0.00263	CcSEcCtD
Epoprostenol—Dizziness—Vinblastine—head and neck cancer	0.00192	0.00263	CcSEcCtD
Epoprostenol—Oedema peripheral—Docetaxel—head and neck cancer	0.00191	0.00261	CcSEcCtD
Epoprostenol—Oedema—Fluorouracil—head and neck cancer	0.00191	0.00261	CcSEcCtD
Epoprostenol—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00191	0.00261	CcSEcCtD
Epoprostenol—Connective tissue disorder—Docetaxel—head and neck cancer	0.0019	0.0026	CcSEcCtD
Epoprostenol—Asthenia—Hydroxyurea—head and neck cancer	0.0019	0.0026	CcSEcCtD
Epoprostenol—Infection—Fluorouracil—head and neck cancer	0.0019	0.00259	CcSEcCtD
Epoprostenol—Nervous system disorder—Fluorouracil—head and neck cancer	0.00187	0.00256	CcSEcCtD
Epoprostenol—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00187	0.00255	CcSEcCtD
Epoprostenol—Tachycardia—Fluorouracil—head and neck cancer	0.00186	0.00255	CcSEcCtD
Epoprostenol—Vomiting—Vinblastine—head and neck cancer	0.00185	0.00253	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—GRP—head and neck cancer	0.00183	0.0068	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—GRP—head and neck cancer	0.00183	0.0068	CbGpPWpGaD
Epoprostenol—Headache—Vinblastine—head and neck cancer	0.00182	0.00249	CcSEcCtD
Epoprostenol—Anorexia—Fluorouracil—head and neck cancer	0.00182	0.00249	CcSEcCtD
Epoprostenol—Diarrhoea—Hydroxyurea—head and neck cancer	0.00181	0.00248	CcSEcCtD
Epoprostenol—Cardiac disorder—Docetaxel—head and neck cancer	0.0018	0.00246	CcSEcCtD
Epoprostenol—Flushing—Docetaxel—head and neck cancer	0.0018	0.00246	CcSEcCtD
Epoprostenol—Hypotension—Fluorouracil—head and neck cancer	0.00178	0.00244	CcSEcCtD
Epoprostenol—Angiopathy—Docetaxel—head and neck cancer	0.00176	0.0024	CcSEcCtD
Epoprostenol—Dizziness—Hydroxyurea—head and neck cancer	0.00175	0.0024	CcSEcCtD
Epoprostenol—Mediastinal disorder—Docetaxel—head and neck cancer	0.00175	0.00239	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.00174	0.00649	CbGpPWpGaD
Epoprostenol—Chills—Docetaxel—head and neck cancer	0.00174	0.00238	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00174	0.00238	CcSEcCtD
Epoprostenol—Nausea—Vinblastine—head and neck cancer	0.00173	0.00236	CcSEcCtD
Epoprostenol—Insomnia—Fluorouracil—head and neck cancer	0.00173	0.00236	CcSEcCtD
Epoprostenol—Paraesthesia—Fluorouracil—head and neck cancer	0.00171	0.00234	CcSEcCtD
Epoprostenol—Dyspnoea—Fluorouracil—head and neck cancer	0.0017	0.00233	CcSEcCtD
Epoprostenol—Mental disorder—Docetaxel—head and neck cancer	0.0017	0.00232	CcSEcCtD
Epoprostenol—Somnolence—Fluorouracil—head and neck cancer	0.0017	0.00232	CcSEcCtD
Epoprostenol—Vomiting—Hydroxyurea—head and neck cancer	0.00169	0.0023	CcSEcCtD
Epoprostenol—Dyspepsia—Fluorouracil—head and neck cancer	0.00168	0.0023	CcSEcCtD
Epoprostenol—Rash—Hydroxyurea—head and neck cancer	0.00167	0.00229	CcSEcCtD
Epoprostenol—Dermatitis—Hydroxyurea—head and neck cancer	0.00167	0.00228	CcSEcCtD
Epoprostenol—Headache—Hydroxyurea—head and neck cancer	0.00166	0.00227	CcSEcCtD
Epoprostenol—Decreased appetite—Fluorouracil—head and neck cancer	0.00166	0.00227	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00165	0.00225	CcSEcCtD
Epoprostenol—Back pain—Docetaxel—head and neck cancer	0.00163	0.00223	CcSEcCtD
Epoprostenol—Pain—Fluorouracil—head and neck cancer	0.00163	0.00223	CcSEcCtD
Epoprostenol—Muscle spasms—Docetaxel—head and neck cancer	0.00162	0.00222	CcSEcCtD
Epoprostenol—Nausea—Hydroxyurea—head and neck cancer	0.00157	0.00215	CcSEcCtD
Epoprostenol—Anaemia—Docetaxel—head and neck cancer	0.00156	0.00213	CcSEcCtD
Epoprostenol—Urticaria—Fluorouracil—head and neck cancer	0.00152	0.00207	CcSEcCtD
Epoprostenol—Syncope—Docetaxel—head and neck cancer	0.00151	0.00207	CcSEcCtD
Epoprostenol—Body temperature increased—Fluorouracil—head and neck cancer	0.00151	0.00206	CcSEcCtD
Epoprostenol—Palpitations—Docetaxel—head and neck cancer	0.00149	0.00204	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—STAT3—head and neck cancer	0.00148	0.00552	CbGpPWpGaD
Epoprostenol—Loss of consciousness—Docetaxel—head and neck cancer	0.00148	0.00203	CcSEcCtD
Epoprostenol—Cough—Docetaxel—head and neck cancer	0.00147	0.00201	CcSEcCtD
Epoprostenol—Chest pain—Docetaxel—head and neck cancer	0.00144	0.00196	CcSEcCtD
Epoprostenol—Myalgia—Docetaxel—head and neck cancer	0.00144	0.00196	CcSEcCtD
Epoprostenol—Arthralgia—Docetaxel—head and neck cancer	0.00144	0.00196	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00143	0.00195	CcSEcCtD
Epoprostenol—Hypersensitivity—Fluorouracil—head and neck cancer	0.00141	0.00192	CcSEcCtD
Epoprostenol—Dry mouth—Docetaxel—head and neck cancer	0.0014	0.00192	CcSEcCtD
Epoprostenol—Confusional state—Docetaxel—head and neck cancer	0.00139	0.0019	CcSEcCtD
Epoprostenol—Oedema—Docetaxel—head and neck cancer	0.00138	0.00188	CcSEcCtD
Epoprostenol—Anaphylactic shock—Docetaxel—head and neck cancer	0.00138	0.00188	CcSEcCtD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—AKT1—head and neck cancer	0.00137	0.00511	CbGpPWpGaD
Epoprostenol—Infection—Docetaxel—head and neck cancer	0.00137	0.00187	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—KISS1—head and neck cancer	0.00136	0.00507	CbGpPWpGaD
Epoprostenol—Shock—Docetaxel—head and neck cancer	0.00135	0.00185	CcSEcCtD
Epoprostenol—Nervous system disorder—Docetaxel—head and neck cancer	0.00135	0.00185	CcSEcCtD
Epoprostenol—Pruritus—Fluorouracil—head and neck cancer	0.00135	0.00185	CcSEcCtD
Epoprostenol—Thrombocytopenia—Docetaxel—head and neck cancer	0.00135	0.00184	CcSEcCtD
Epoprostenol—Tachycardia—Docetaxel—head and neck cancer	0.00134	0.00184	CcSEcCtD
Epoprostenol—Skin disorder—Docetaxel—head and neck cancer	0.00134	0.00183	CcSEcCtD
Epoprostenol—Anorexia—Docetaxel—head and neck cancer	0.00131	0.0018	CcSEcCtD
Epoprostenol—Diarrhoea—Fluorouracil—head and neck cancer	0.00131	0.00179	CcSEcCtD
Epoprostenol—Hypotension—Docetaxel—head and neck cancer	0.00129	0.00176	CcSEcCtD
Epoprostenol—Dizziness—Fluorouracil—head and neck cancer	0.00126	0.00173	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00125	0.00172	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—KISS1—head and neck cancer	0.00125	0.00466	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—KISS1—head and neck cancer	0.00125	0.00466	CbGpPWpGaD
Epoprostenol—Insomnia—Docetaxel—head and neck cancer	0.00125	0.0017	CcSEcCtD
Epoprostenol—Paraesthesia—Docetaxel—head and neck cancer	0.00124	0.00169	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—KISS1—head and neck cancer	0.00124	0.0046	CbGpPWpGaD
Epoprostenol—Dyspnoea—Docetaxel—head and neck cancer	0.00123	0.00168	CcSEcCtD
Epoprostenol—Somnolence—Docetaxel—head and neck cancer	0.00122	0.00167	CcSEcCtD
Epoprostenol—Vomiting—Fluorouracil—head and neck cancer	0.00121	0.00166	CcSEcCtD
Epoprostenol—Dyspepsia—Docetaxel—head and neck cancer	0.00121	0.00166	CcSEcCtD
Epoprostenol—Rash—Fluorouracil—head and neck cancer	0.0012	0.00165	CcSEcCtD
Epoprostenol—Dermatitis—Fluorouracil—head and neck cancer	0.0012	0.00164	CcSEcCtD
Epoprostenol—Decreased appetite—Docetaxel—head and neck cancer	0.0012	0.00164	CcSEcCtD
Epoprostenol—Headache—Fluorouracil—head and neck cancer	0.0012	0.00163	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00119	0.00163	CcSEcCtD
Epoprostenol—Fatigue—Docetaxel—head and neck cancer	0.00119	0.00162	CcSEcCtD
Epoprostenol—Constipation—Docetaxel—head and neck cancer	0.00118	0.00161	CcSEcCtD
Epoprostenol—Pain—Docetaxel—head and neck cancer	0.00118	0.00161	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—KISS1—head and neck cancer	0.00114	0.00423	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KISS1—head and neck cancer	0.00114	0.00423	CbGpPWpGaD
Epoprostenol—Nausea—Fluorouracil—head and neck cancer	0.00113	0.00155	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00113	0.00154	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00112	0.00417	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—GRP—head and neck cancer	0.00112	0.00417	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00111	0.00413	CbGpPWpGaD
Epoprostenol—Abdominal pain—Docetaxel—head and neck cancer	0.00109	0.00149	CcSEcCtD
Epoprostenol—Body temperature increased—Docetaxel—head and neck cancer	0.00109	0.00149	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—GRP—head and neck cancer	0.00103	0.00384	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—GRP—head and neck cancer	0.00103	0.00384	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—GRP—head and neck cancer	0.00102	0.00379	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Docetaxel—head and neck cancer	0.00101	0.00139	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000992	0.00369	CbGpPWpGaD
Epoprostenol—Asthenia—Docetaxel—head and neck cancer	0.000988	0.00135	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000982	0.00365	CbGpPWpGaD
Epoprostenol—Pruritus—Docetaxel—head and neck cancer	0.000974	0.00133	CcSEcCtD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000959	0.00357	CbGpPWpGaD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000947	0.00352	CbGpPWpGaD
Epoprostenol—Diarrhoea—Docetaxel—head and neck cancer	0.000942	0.00129	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—GRP—head and neck cancer	0.000937	0.00349	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—GRP—head and neck cancer	0.000937	0.00349	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NAT2—head and neck cancer	0.000934	0.00348	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IL2—head and neck cancer	0.000917	0.00341	CbGpPWpGaD
Epoprostenol—Dizziness—Docetaxel—head and neck cancer	0.000911	0.00125	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000882	0.00328	CbGpPWpGaD
Epoprostenol—Vomiting—Docetaxel—head and neck cancer	0.000876	0.0012	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.00087	0.00324	CbGpPWpGaD
Epoprostenol—Rash—Docetaxel—head and neck cancer	0.000868	0.00119	CcSEcCtD
Epoprostenol—Dermatitis—Docetaxel—head and neck cancer	0.000868	0.00119	CcSEcCtD
Epoprostenol—Headache—Docetaxel—head and neck cancer	0.000863	0.00118	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—DPYD—head and neck cancer	0.000819	0.00305	CbGpPWpGaD
Epoprostenol—Nausea—Docetaxel—head and neck cancer	0.000818	0.00112	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	0.000779	0.0029	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000778	0.00289	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—YAP1—head and neck cancer	0.000777	0.00289	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	0.000737	0.00274	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KISS1—head and neck cancer	0.00073	0.00272	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	0.000702	0.00261	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.000694	0.00258	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KISS1—head and neck cancer	0.000672	0.0025	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KISS1—head and neck cancer	0.000672	0.0025	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.00066	0.00246	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.00066	0.00246	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.00066	0.00246	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.00064	0.00238	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	0.000609	0.00227	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GRP—head and neck cancer	0.000601	0.00224	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT6—head and neck cancer	0.000584	0.00217	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000584	0.00217	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000573	0.00213	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GRP—head and neck cancer	0.000554	0.00206	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GRP—head and neck cancer	0.000554	0.00206	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT6—head and neck cancer	0.000537	0.002	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT6—head and neck cancer	0.000537	0.002	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.00053	0.00197	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—YAP1—head and neck cancer	0.000517	0.00192	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000509	0.00189	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	0.000497	0.00185	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—YAP1—head and neck cancer	0.000476	0.00177	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—YAP1—head and neck cancer	0.000476	0.00177	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—IL2—head and neck cancer	0.000473	0.00176	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—TYMS—head and neck cancer	0.000467	0.00174	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTM1—head and neck cancer	0.000461	0.00172	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GPX1—head and neck cancer	0.000442	0.00164	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP1A1—head and neck cancer	0.000437	0.00163	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	0.000436	0.00162	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IL2—head and neck cancer	0.000435	0.00162	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	0.00043	0.0016	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NOTCH1—head and neck cancer	0.000418	0.00156	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	0.000413	0.00154	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000407	0.00152	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—head and neck cancer	0.000402	0.0015	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MAPK3—head and neck cancer	0.00038	0.00141	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—head and neck cancer	0.00037	0.00138	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UROD—head and neck cancer	0.000363	0.00135	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MAPK1—head and neck cancer	0.000362	0.00135	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000359	0.00134	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—MAPK3—head and neck cancer	0.00035	0.0013	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—MAPK1—head and neck cancer	0.000333	0.00124	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PIK3CA—head and neck cancer	0.000314	0.00117	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—head and neck cancer	0.00031	0.00116	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—head and neck cancer	0.000304	0.00113	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2—head and neck cancer	0.000299	0.00111	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—head and neck cancer	0.00029	0.00108	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PIK3CA—head and neck cancer	0.000289	0.00107	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000282	0.00105	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—head and neck cancer	0.000279	0.00104	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2—head and neck cancer	0.000275	0.00102	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2—head and neck cancer	0.000275	0.00102	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—head and neck cancer	0.000271	0.00101	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—head and neck cancer	0.000271	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—head and neck cancer	0.000267	0.000994	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—head and neck cancer	0.00026	0.000968	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—head and neck cancer	0.000256	0.000954	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—head and neck cancer	0.00025	0.000929	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—head and neck cancer	0.00025	0.000929	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—head and neck cancer	0.000242	0.000901	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—head and neck cancer	0.000236	0.000878	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH1—head and neck cancer	0.000233	0.000867	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK3—head and neck cancer	0.000231	0.000861	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—head and neck cancer	0.000227	0.000844	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK1—head and neck cancer	0.00022	0.000819	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—head and neck cancer	0.00022	0.000819	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK3—head and neck cancer	0.000218	0.000812	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH1—head and neck cancer	0.000214	0.000798	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH1—head and neck cancer	0.000214	0.000798	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK1—head and neck cancer	0.000208	0.000772	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—head and neck cancer	0.000208	0.000772	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK3—head and neck cancer	0.000201	0.000747	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK3—head and neck cancer	0.000201	0.000747	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000198	0.000738	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—head and neck cancer	0.000191	0.000711	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK1—head and neck cancer	0.000191	0.000711	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK1—head and neck cancer	0.000191	0.000711	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—head and neck cancer	0.000191	0.000711	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—head and neck cancer	0.000191	0.000711	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000183	0.000679	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000183	0.000679	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—head and neck cancer	0.00018	0.00067	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—head and neck cancer	0.000177	0.000658	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—head and neck cancer	0.000167	0.00062	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—head and neck cancer	0.000166	0.000617	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—head and neck cancer	0.000166	0.000617	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—head and neck cancer	0.000162	0.000603	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—head and neck cancer	0.00016	0.000596	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.00016	0.000596	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—head and neck cancer	0.00016	0.000595	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000159	0.00059	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—head and neck cancer	0.000156	0.000581	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—head and neck cancer	0.000156	0.000581	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—head and neck cancer	0.000153	0.000571	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—head and neck cancer	0.000153	0.000571	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NAT2—head and neck cancer	0.000151	0.000562	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—head and neck cancer	0.000151	0.000561	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—head and neck cancer	0.000149	0.000555	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—head and neck cancer	0.000149	0.000555	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—head and neck cancer	0.000148	0.000549	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—head and neck cancer	0.000148	0.000549	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—head and neck cancer	0.000147	0.000548	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—head and neck cancer	0.000144	0.000535	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—head and neck cancer	0.000144	0.000535	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—head and neck cancer	0.000139	0.000516	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—head and neck cancer	0.000139	0.000516	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—head and neck cancer	0.000136	0.000507	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—head and neck cancer	0.000135	0.000504	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—head and neck cancer	0.000135	0.000504	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—head and neck cancer	0.000135	0.000502	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DPYD—head and neck cancer	0.000132	0.000492	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—head and neck cancer	0.000131	0.000486	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK3—head and neck cancer	0.000129	0.00048	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—YAP1—head and neck cancer	0.000126	0.000467	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—head and neck cancer	0.000125	0.000467	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—head and neck cancer	0.000125	0.000467	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—head and neck cancer	0.000124	0.000462	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—head and neck cancer	0.000124	0.000462	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK1—head and neck cancer	0.000123	0.000456	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—head and neck cancer	0.000123	0.000456	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK3—head and neck cancer	0.000119	0.000441	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK3—head and neck cancer	0.000119	0.000441	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK1—head and neck cancer	0.000113	0.00042	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK1—head and neck cancer	0.000113	0.00042	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—head and neck cancer	0.000113	0.00042	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—head and neck cancer	0.000113	0.00042	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—head and neck cancer	0.000106	0.000396	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—head and neck cancer	0.000103	0.000383	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—head and neck cancer	9.84e-05	0.000366	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—head and neck cancer	9.79e-05	0.000364	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—head and neck cancer	9.79e-05	0.000364	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—head and neck cancer	9.47e-05	0.000352	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—head and neck cancer	9.47e-05	0.000352	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	9.43e-05	0.000351	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—head and neck cancer	9.06e-05	0.000337	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—head and neck cancer	9.06e-05	0.000337	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—head and neck cancer	8.69e-05	0.000323	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.23e-05	0.000306	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—head and neck cancer	8e-05	0.000298	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—head and neck cancer	8e-05	0.000298	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMS—head and neck cancer	7.54e-05	0.000281	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—head and neck cancer	7.45e-05	0.000277	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX1—head and neck cancer	7.14e-05	0.000266	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A1—head and neck cancer	7.07e-05	0.000263	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.8e-05	0.000216	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—head and neck cancer	4.2e-05	0.000156	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—head and neck cancer	3.66e-05	0.000136	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—head and neck cancer	2.59e-05	9.62e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—head and neck cancer	2.11e-05	7.86e-05	CbGpPWpGaD
